Is low- versus standard-dose alteplase equally effective in acute lacunar ischemic stroke?

Takeaway

  • Low-dose alteplase does not provide additional benefits over standard-dose alteplase in people with lacunar acute ischemic stroke.

Why this matters

    In the alteplase-dose arm of the Enhanced Control of Hypertension and Thrombolysis Stroke Study, a lower dose of intravenous alteplase was linked to reduced risk of intracerebral hemorrhage versus the standard-dose in thrombolysis-eligible acute ischemic stroke individuals. This study investigated whether this is also true for lacunar acute ischemic stroke. The findings suggest that people with lacunar acute ischemic stroke should receive standard dose intravenous alteplase as with other acute ischemic stroke subtypes.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.